Quanterix tech helps measure Crohn's biomarkers

Quanterix, of Cambridge, MA, is touting its Single Molecule Array (SiMoA) technology in helping to measure inflammation biomarkers among patients with Crohn's disease. Crohn's is an inflammatory disease of the intestines that causes abdominal pain, diarrhea or weight loss, among many other possible symptoms.

Quanterix precisely measured low levels of cell-signalling proteins called cytokines using its digital enzyme-linked immunosorbent assay. The results showed that anti-TNF-α drugs reduced cytokine concentrations. TNF, or tumor necrosis factor, promotes inflammation, which in turn causes the symptoms of Crohn's disease. TNF alpha blockers are used as treatments. Inflammatory cytokines like TNF-α can initiate Crohn's disease symptoms.

"Although larger studies will be needed to fully understand the potential utility of cytokine measurements in the diagnosis of inflammatory diseases such as Crohn's, these results provide some indication of how sensitive and precise protein measurements enabled by SiMoA could be used clinically," Quanterix Executive Chairman Martin Madaus said in a statement.

- read more in the Quanterix release

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.